Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Lithuania IVD Market by Technology Molecular Diagnostics, Cytomegalovirus, Epstein–Barr virus, Tuberculosis, Sexually Transmitted Diseases, Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus, Covid- 19), Tissue Diagnostics, Sequencing Geography, and forecast to 2029
Lithuania IVD market size was valued at Euro 42.5 million in 2022 and is poised to grow at a significant CAGR of 3.6% over 2023–2029. The Lithuania in-vitro diagnostics (IVD) market is a dynamic and rapidly evolving sector within the healthcare industry. IVD refers to medical devices and diagnostic techniques that are used to analyze samples derived from the human body, such as blood, urine, and tissue, outside the body. These tests provide crucial information for the early detection, diagnosis, and management of diseases and conditions. Molecular diagnostics in IVD market are growing at fastest rate due to increasing prevalence of various diseases such as Hepatitis B and C, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV) and Covid- 19. In Lithuania, regular screening for blood donations is mostly done with NAT-based assays. Hepatitis C testing is also done on other demographic groups, such as medical staff, military people, and pregnant women, and is frequently done as part of clinical and scientific research. Every year, 1,500-2,000 persons in Lithuania infect with Hepatitis B, with around 100 of them developing jaundice. Within 6 months of developing acute viral hepatitis B, 90-98 percent of individuals recover fully and develop natural immunity. 5% of persons infected with HBV become chronic carriers, producing HBsAg and HBV-DNA on a long-term basis, and these infected donors are diagnosed by serology and NAT. HIV infections were reported in practically all administrative units of 60 municipalities in Lithuania. According to the ECDC report 2021, the number of newly diagnosed HIV cases gradually increased till 2017 and a downward trend was observed from 2017 to 2020. In 2017, the 263 new cases were recorded, and it reached to 108 cases by the end of 2020. Hospital-acquired infection is very high in Lithuania. Surgical site infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and healthcare-associated pneumonia, infections linked with endoscopic treatments, and Clostridium difficile infections are the most common hospital-acquired infections in Lithuania.
In Lithuania, high growth areas in infectious diseases are HPV, STDs, Respiratory Infections, Hospital Acquired infections (HAIs) and oncology markers. Tissue diagnostics and sequencing in Lithuania IVD market also accounted for the high market value. The prevalence of various diseases and investment in healthcare infrastructure are driving market growth. Human papillomavirus (HPV) is a prevalent sexually transmitted infection (STI) linked to cervical cancer. The increasing awareness about the importance of HPV vaccination and its effectiveness in preventing cervical cancer has led to a higher demand for screening and diagnostic tests for HPV in Lithuania.
Sequencing is a set of procedures for determining the fundamental structure of an unbranched biopolymer (DNA, RNA, protein, or carbohydrate), which results in a symbolic linear representation of the monomeric subunits that summarizes most of the molecule's atomic structure. In 2022, 18,901 sequencing tests are carried out in Lithuania. Majority of the sequencing tests are research use only and clinical has little share in the sequencing testing. NIPT is gaining attention across the country owing to its non-invasive nature. Non-invasive prenatal testing (NIPT), using cell-free fetal DNA, has increasingly been adopted as a screening tool for fetal aneuploidies.
Report Benchmarks |
Details |
By Technology |
|
By Technology |
|
By Technology |
|
Download Free Sample Report
The Lithuania IVD market is valued at Euro 42.5 million in 2022 and is poised to grow at a significant CAGR of 3.6% over 2023–2029.
QIAGEN, Bio-Rad Laboratories, Interlab Services, Roche Diagnostics, Thermofisher Scientific, Seegene, Inc., Cepheid, Inc., Abbott, Inc., Illumina, Inc., Dako, Leica, and Abbott
Covid-19 infection is accounted for Euro 30.6 Mn in 2022. Hospital-acquired infection (HAI) is the second highest disease accounting for Euro1.2 Mn and is expected to reach Euro 1.6 Mn by 2029.
Molecular diagnostics technology is expected to drive market growth due to fast and accurate results. sequencing accounted for the 2nd highest market value of Euro 5.8 Mn in 2022 and is expected to reach Euro 7.5 Mn by 2029. In 2022, 18,901 sequencing tests are carried out in Lithuania.
Key Market Players